Integrating tuberculosis and HIV services for people living with HIV: costs of the Zambian ProTEST Initiative.

Cost Effectiveness and Resource Allocation : C/E
Fern Terris-PrestholtP Godfrey-Faussett

Abstract

In the face of the dual TB/HIV epidemic, the ProTEST Initiative was one of the first to demonstrate the feasibility of providing collaborative TB/HIV care for people living with HIV (PLWH) in poor settings. The ProTEST Initiative facilitated collaboration between service providers. Voluntary counselling and testing (VCT) acted as the entry point for services including TB screening and preventive therapy, clinical treatment for HIV-related disease, and home-based care (HBC), and a hospice. This paper estimates the costs of the ProTEST Initiative in two sites in urban Zambia, prior to the introduction of anti-retroviral therapy. Annual financial and economic providers costs and output measures were collected in 2000-2001. Estimates are made of total costs for each component and average costs per: person reached by ProTEST; VCT pre-test counselled, tested and completed; isoniazid preventive therapy started and completed; clinic visit; HBC patient; and hospice admission and bednight. Annual core ProTEST costs were (in 2007 US dollars) $84,213 in Chawama and $31,053 in Matero. The cost of coordination was 4%-5% of total site costs ($1-$6 per person reached). The largest cost component in Chawama was voluntary counselling and testing...Continue Reading

References

Dec 23, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·A D HarriesP Nunn
Oct 31, 2001·AIDS·J L JohnsonUNKNOWN Uganda-Case Western Reserve University Research Collaboration
May 10, 2002·Health Policy and Planning·Steven ForsytheCharles Gilks
Jun 26, 2003·Public Health Nursing·Leana R Uys
Jun 7, 2005·Lancet·Richard Harding, Irene J Higginson
Oct 1, 2005·BMJ : British Medical Journal·Catherine SenyimbaRichard Harding
Jun 15, 2006·BMC Infectious Diseases·Tom A SzakacsAnne E McCarthy
Aug 1, 2006·Bulletin of the World Health Organization·Harry Peter HauslerPeter Godfrey-Faussett
Aug 15, 2006·JAMA : the Journal of the American Medical Association·Jeffrey S A StringerMoses Sinkala
Nov 1, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fulgentius BaryaramaJonathan H Mermin
Jul 25, 2008·AIDS·Greg SzekeresAnke A Ehrhardt
Apr 17, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·P NakaggwaE Bloss

❮ Previous
Next ❯

Citations

Feb 18, 2011·Clinical Epidemiology·Christopher Au-YeungEdward J Mills
Jun 15, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Eduard J BeckPaul De Lay
Dec 12, 2012·Tropical Medicine & International Health : TM & IH·Helena Legido-QuigleyAlison D Grant
Aug 8, 2015·Research in Social & Administrative Pharmacy : RSAP·Natali JokanovicJ Simon Bell
Oct 17, 2017·PloS One·Lawrence MwengeFern Terris-Prestholt

❮ Previous
Next ❯

Software Mentioned

ProTEST
ZAMBART
Matero

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Tropical Medicine & International Health : TM & IH
Adiatma Y M SiregarRob Baltussen
PLoS Medicine
Rochelle P Walensky, Ingrid V Bassett
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Molly F FrankeCarole D Mitnick
Journal of Acquired Immune Deficiency Syndromes : JAIDS
Ingrid V BassettKenneth A Freedberg
The New England Journal of Medicine
Myron S CohenHPTN 052 Study Team
© 2021 Meta ULC. All rights reserved